New Analysis Suggests Long-Term Effectiveness for Wegovy Users from of side Watch Video

⏲ Duration: 1:31
👁 View: 880K times
✓ Published: 15-May-2024

Description:
New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand